2012


To access this material please log in or register

Register Authorize
2012/№5

Thrombophilic status in chronic heart failure patients with Atrial Fibrillation

Korobchenko E. E., Shaposhnik I. I.

Keywords: heart failure, thrombophilic status, atrial fibrillation

DOI: 10.18087/rhfj.2012.5.1714

Relevance. Atrial fibrillation (AF) can be both effect and cause of HF, which is also of high risk of thromboembolic complications. The essential part in this complications might be that of hemostasis status. Objective. Reveal hemostasis features in AF and HF patients. Materials and methods. 167 patients at the age of 47–79 were examined. Patients were divided in two groups depending on presence of AF. Along with common clinical tests, patients underwent diagnosis of all three hemostasis links. Results. With more severe HF, AF patients tend to have increased thrombocyte aggregation induced by the various doses of ACE and collagen. There were significant intergroup distinctions of levels of tissue thromboplastin I activation inhibitor (113±77.3 in group of AF patients and 100±133 in group of non-AF patients) and soluble fibrin monomer complexes (10.9±5.64 and 8.29±3.62, relatively). Significant distinctions of D-dimer levels were found in patients with and without AF, and in with the various CHF FC. Conclusion. AF patients with HF getting more severe have hemostasis disbalance with trend to thrombogenesis. Atrial fibrillation makes HF course more severe and aggravates thrombogenic shifts in all links of the hemostasis.
  1. Терещенко С. Н., Ускач Т. М., Кочетов А. Г. Тромбозы и тромбоэмболии при хронической сердечной недостаточности и их профилактика. – М., «Анахарсис», 2004. –86с.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  3. Национальные рекомендации ВНОК и ВНОА по диагностике и лечению фибрилляции предсердий, 2011 г. (Проект). Доступно на: http://www.kardioforum.ru / files / articles / files / 3005_1.pdf
  4. Зотова И. В., Затейщиков Д. А., Сидоренко Б. А. Предикторы внутрисердечного тромбоза у больных с мерцательной аритмией: факторы гемостаза, маркеры воспалений и генетические факторы. Кардиология. 2007;47 (11):36–40.
  5. Camm AJ, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (deve­loped with the special contribution of the European Heart Rhythm Association, endorsed by the European Association for Cardio-Thoracic Surgery). Eur Heart J. 2010;31 (19):2369–2429.
  6. Панченко Е. П., Кропачева Е. С. Профилактика тромбоэмболий у больных мерцательной аритмией. – М.: «МИА», 2007–144 с.
  7. Benjamin EJ, D'Agostino RB, Belanger AJ et al. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995;92 (4):835–841.
  8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22 (8):983–988.
  9. Шмелева В. М., Семенова О. Н., Папаян Л. П. и др. Активация системы гемостаза у пациентов с хронической сердечной недостаточностью. Вестник Санкт-Петербургского Университета. 2009;11 (1):37-43.
Korobchenko E. E., Shaposhnik I. I. Thrombophilic status in chronic heart failure patients with Atrial Fibrillation. Russian Heart Failure Journal. 2012;13(5):279-282

To access this material please log in or register

Register Authorize
Ru En